Showing results (291-300 of 366) with videos related to
Sort By:
Pageof 37
Cancer Research|August 4, 2006
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomographyJulius Leyton, John P Alao, Marco Da Costa, et al.Molecular Cancer Therapeutics|December 20, 2007
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activityFlorence Chan, Chongbo Sun, Meg Perumal, et al.Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.Chemistry & Biology|June 26, 2004
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoformsLisa Wright, Xavier Barril, Brian Dymock, et al.Journal of Medicinal Chemistry|March 19, 2008
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaborationJohn J Caldwell, Thomas G Davies, Alastair Donald, et al.Molecular & Cellular Proteomics : MCP|December 22, 2022
Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global ChangesRahul S Samant, Silvia Batista, Mark Larance, et al.Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.Cancer Research|December 24, 2011
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancersMounia Beloueche-Babari, Vaitha Arunan, Helen Troy, et al.Nucleic Acids Research|November 21, 2020
canSAR: update to the cancer translational research and drug discovery knowledgebaseCostas Mitsopoulos, Patrizio Di Micco, Eloy Villasclaras Fernandez, et al.Oncotarget|July 21, 2016
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsLynsey Vaughan, Paul A Clarke, Karen Barker, et al.Pageof 37